1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* 2004;21:137–148.
2. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. *J Oncol* 2010;2010:932371.
3. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. *J Clin Oncol* 2008;26:5284–5293.
4. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. *Endocr Rev* 2001;22:255–288.
5. Wright JW, Pejovic T, Fanton J, et al. Induction of proliferation in the primate ovarian surface epithelium in vivo. *Hum Reprod* 2008;23:129–138.
6. Wright JW, Pejovic T, Lawson M, et al. Ovulation in the absence of the ovarian surface epithelium in the primate. *Biol Reprod* 2010;82:599–605.
7. Schlosshauer PW, Cohen CJ, Penault-Llorca F, et al. Prophylactic oophorectomy: a morphologic and immunohistochemical study. *Cancer* 2003;98:2599–2606.
8. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. *J Clin Oncol* 2007;25:3985–3990.
9. Tone AA, Begley H, Sharma M, et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. *Clin Cancer Res* 2008;14:4067–4078.
10. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. *Ann Oncol* 2013;24:x16–x21.
11. Ramus SJ. Current status of inherited predisposition to ovarian cancer: lessons from familial ovarian cancer registries in the UK and USA. In: Odunsi K, Pejovic T, eds. *Gynecologic Cancer: A Multidisciplinary Approach to Diagnosis and Management*. New York: Demos Medical; 2013.
12. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. *Mol Oncol* 2009;3:138–150.
13. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66–71.
14. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature* 1995;378:789–792.
15. Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. *Hum Mutat* 2005;25:415–422.
16. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. *Future Oncol* 2006;2:257–274.
17. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Mol Cell* 2001;7:249–262.
18. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 2008;451:1116–1120.
19. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. *Proc Natl Acad Sci U S A* 2010;107:12629–12633.
20. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. *Oncogene* 2007;26:7816–7824.
21. Bradford L, Ambrosio A, Birrer MJ. PARP Inhibitors in gyecologic malignancies. In: Odunsi K, Pejovic T, eds. *Gynecologic Cancers: A Multidisciplinary Approach to Diagnosis and Management*. New York: Demos Medical; 2013.
22. Musrap N, Diamandis EP. Revisiting the complexity of the ovarian cancer microenvironment—clinical implications for treatment strategies. *Mol Cancer Res* 2012;10:1254–1264.
23. Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. *Cancer Res* 2007;67:585–592.
24. Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. *J Clin Invest* 2009;119:3011–3023.
25. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. *Clin Cancer Res* 2011;17:6083–6096.
26. Ren J, Xiao YJ, Singh LS, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. *Cancer Res* 2006;66:3006–3014.
27. Sengupta S, Kim KS, Berk MP, et al. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. *Oncogene* 2007;26:2894–2901.
28. Do TV, Symowicz JC, Berman DM, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. *Mol Cancer Res* 2007;5:121–131.
29. Martinet L, Poupot R, Mirshahi P, et al. Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. *Int J Cancer* 2010;126:2143–2152.
30. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. *Ann Med* 1995;27:79–85.
31. Turk MJ, Waters DJ, Low PS. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. *Cancer Lett* 2004;213:165–172.
32. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. *J Clin Oncol* 2010;28:3107–3114.
33. Mabuchi S, Hisamatsu T, Kawase C, et al. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. *Clin Cancer Res* 2011;17:4462–4473.
34. Jiang J, Chen W, Zhuang R, et al. The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro. *J Cancer Res Clin Oncol* 2010;136:873–881.
35. Khanna M, Chelladurai B, Gavini A, et al. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. *Mol Cancer Ther* 2011;10:626–636.
36. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. *Clin Biochem* 2004;37:363–369.
37. Jiang H, Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. *Int J Gynecol Cancer* 2006;16:405–412.
38. Zhu G, Saed GM, Deppe G, et al. Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. *Gynecol Oncol* 2004;94:422–426.
39. Imai T, Horiuchi A, Wang C, et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. *Am J Pathol* 2003;163:1437–1447.
40. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011;365:2473–2483.
41. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? *Nat Rev Cancer* 2006;6:107–116.
42. Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. *Clin Cancer Res* 2002;8:2246–2252.
43. Balch C, Huang TH, Brown R, et al. The epigenetics of ovarian cancer drug resistance and resensitization. *Am J Obstet Gynecol* 2004;191:1552–1572.
44. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 2003;348:203–213.
45. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. *Adv Immunol* 2006;90:1–50.
46. Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. *J Clin Oncol* 2006;24:762–768.
47. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. *Cancer Res* 2003;63:6076–6083.
48. Old LJ. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. *Cancer Immun* 2001;1:1.
49. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proc Natl Acad Sci U S A* 2010;107:7875–7880.
50. Odunsi K, Qian F, Matsuzaki J, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. *Proc Natl Acad Sci U S A* 2007;104:12837–12842.
51. Odunsi K, Matsuzaki J, Karbach J, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. *Proc Natl Acad Sci U S A* 2012;109:5797–5802.
52. Chiang CL, Kandalaft LE, Tanyi J, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. *Clin Cancer Res* 2013;19:4801–4815.
53. Kandalaft LE, Chiang CL, Tanyi J, et al. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. *J Transl Med* 2013;11:149.
54. Mutter GL, Boynton KA, Faquin WC, et al. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. *Cancer Res* 1996;56:4483–4486.
55. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. *J Natl Cancer Inst* 2000;92:924–930.
56. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. *Am J Pathol* 1995;146:182–188.
57. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. *Cancer Res* 1999;59:3346–3351.
58. Busmanis I, Ho TH, Tan SB, et al. p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium. *Ann Acad Med Singapore* 2005;34:421–425.

59. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. *J Natl Cancer Inst* 2000;92:690–698.
60. Shope RE. Serial transmission of virus of infectious paillomatosis in domestic rabbits. *Proc Soc Exp Biol Med* 1935;32:830.
61. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. *Cancer Res* 2004;64:3878–3884.
62. Duensing S, Munger K. Centrosome abnormalities, genomic instability and carcinogenic progression. *Biochim Biophys Acta* 2001;1471:M81–M88.
63. Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. *Nature* 2014;506:371–375.
64. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med* 1998;338:423–428.
65. Zhou J, Liu WJ, Peng SW, et al. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. *J Virol* 1999;73:4972–4982.
66. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. *N Engl J Med* 2002;347:1645–1651.
67. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999;189:12–19.
68. Crum CP. The beginning of the end for cervical cancer? *N Engl J Med* 2002;347:1703–1705.